Enter search term

Expanding your diagnostic possibilities.

At ZEUS Scientific, we strive to meet your current and emerging needs by offering more diagnostic choices and enhanced flexibility for your lab. We're continually expanding our broad menu of testing solutions for a growing variety of disease states—and increasing your options across multiple technology platforms and diagnostic testing areas. Rely on us to help you accurately diagnose many critical diseases, and ultimately enhance patient care.

ANA Testing for Autoimmune Diseases

Autoimmune disorders can be difficult to recognize and diagnose, and often lead to highly variable signs and symptoms that may change in severity over time. Laboratory tests to diagnose autoimmune disorders include blood tests for one or more autoantibodies; specifically, antinuclear autoantibodies (ANA).

Discover more choices in ANA testing solutions for connective tissue disease and other autoimmune disorders, with ZEUS IFA, ELISA, or multiplex options.

Lyme Disease

Lyme disease, caused by Borrelia burgdorferi, is the fastest growing vector-borne illness in the United States.

Serological testing in the U.S. has consisted of a standard two-tiered test (STTT) algorithm which can be subjective and lacking in sensitivity. A modified two-tier test (MTTT) algorithm which replaces the second step immunoblot with a more sensitive ELISA test is now FDA-cleared and presents a better alternative that can improve detection of antibodies to Borrelia burgdorferi in early Lyme disease.

Learn more about the ZEUS Borrelia MTTT® algorithm as well as our unique ELISA test systems and see how we’re revolutionizing Lyme disease diagnostics. 


Cardiovascular disease (CVD) is a leading cause of mortality worldwide. The severe clinical consequences of CVD are typically caused by atherosclerotic lesions. The AccuCardia™ Test System utilizes sPLA2-IIA, an emerging biomarker that plays an important role in inflammation and atherosclerosis. The GammaCoeur™ CVD Risk ELISA Test System measures  gamma-prime fibrinogen, an isoform of fibrinogen which is resistant to fibrinolysis, and can lead to more durable clot formations.. These tests enable clinicians to determine a patient's cardiovascular risk and stratify low- and medium-risk CVD patients from high-risk patients.

Human Anti-Murine Antibodies (HAMA)

The development of anti-murine antibodies in a human (the “HAMA response”) can be problematic; causing reactions as mild as a rash or as life-threatening as renal failure. HAMA may also decrease a treatment's efficacy and lead to falsely elevated levels of certain assays.

The ZEUS HAMA IgG ELISA Test System is the only FDA-cleared HAMA test system.  It is ideal for clinical trial managers, laboratories, and developers of diagnostic tests and therapeutics needing to assess the impact of HAMA on their sample sets and products—with fast results in as little as one hour.


Human parvovirus B19 is common and highly contagious, and can cause either minor infection or serious complications depending on the affected individual. The ZEUS ELISA Parvovirus IgG and IgM Test Systems (now U.S. FDA-approved) are the most efficient solutions for pregnancy screening and diagnosis of fifth disease. Achieve accurate results more quickly with our simple, flexible protocol.